1 / 7

JSB Market Research: PharmaPoint: Ulcerative Colitis

During the forecast period from 2012-2022, the growth of the ulcerative colitis market will be driven largely by the entry of Johnson & Johnsons (J&Js) Simponi and Takedas Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. See More: http://goo.gl/tW6DQL

mariapaul
Download Presentation

JSB Market Research: PharmaPoint: Ulcerative Colitis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. i JSB Market Research: PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 To buy this Report Visit http://www.jsbmarketresearch.com

  2. Summary: During the forecast period from 2012-2022, the growth of the ulcerative colitis market will be driven largely by the entry of Johnson & Johnsons (J&Js) Simponi and Takedas Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively. • i

  3. Key Highlights: • The UC market has predominantly been driven by two TNF blockers, namely J&Js Remicade and AbbVies Humira. Although these TNF blockers have monopolized the UC market for almost a decade, the balance is about to be tipped, with Takedas Entyvio imminently entering the market in 2014 and J&Js Simponi launching in 2014 as well, stealing market share from Humira and Remicade. • Remicade and Humira will also be hit by their respective loss of patent protection in 2018 (US), 2015 (EU) and 2016 (US), 2018 (EU). Europe has already approved a biosimilar to Remicade, Celltrions Remsima, which will be marketed by Hospira under the brand name Inflectra in the EU. • To know more about this report click here – • http://www.jsbmarketresearch.com/healthcare-medical/r-PharmaPoint-Ulcerative-Colitis-Global-Drug-Forecast-and-Market-Analysis-114234 • i

  4. Table of Contents: PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 Symptoms 30 Pathophysiology 29 Etiology 26 Quality of Life 31 • i

  5. Related Market Research Report • Molecular Diagnostics Market by Application (Infectious Disease, Oncology, Genetics, Microbiology), Technology (PCR, INAAT, DNA Sequencing), End User (Hospital, Laboratories), Product (Instruments, Reagent, Service, Software) - Global Forecasts to 2018 • Breast Imaging Technologies Market (Analog Mammography, Digital Mammography, Tomosynthesis, Positron Emission Mammography, PET/CT, MBI, Breast MRI, Ultrasound, Optical Imaging, Whole Breast Ultrasound, Breast Thermography) - Global Forecasts to 2019 • Rectal Cancer - Pipeline Review, H2 2014 • Arteriosclerosis - Pipeline Review, H2 2014 • i

  6. About JSB Market Research • Jsbmarketresearch.com is an online repository of an extensive collection of market research reports available online. This online portal contains high-quality reports with well-researched and high-quality content on a wide range of industries. These market research reportshelp us give a detailed insight into new opportunities in the industry, prevailing market trends, competitor analysis and future prospects. • JSB’s reports are developed by the domain experts and publishers under a closely observed surveillance of industry specialists. Therefore, the researched data is well researched, well- organized and matching up to the best standards in the industry. Also JSB’s database consists of detailed insights of the leading players in the global market, products and trends. • i

  7. Contact Us Support & General Inquiries Mail : support@jsbmarketresearch.com| +91 - 998 729 5242 Billing Support Mail : billing@jsbmarketresearch.com | +91 22 412 366 50 Website:- http://www.jsbmarketresearch.com • i

More Related